4520 Main Street
Kansas City, MO
CicloMed Announces ASCO 2018 Presentation on Clinical Trial for Ciclopirox Prodrug, Under Development for Bladder Cancer, 5/31/2018
Antifungal ‘prodrug’ shows promise in bladder cancer: AACR
CicloMed Announces Presentation of Preclinical Evidence for its Bladder Cancer Agent at AACR 2018 Meeting, 4/12/2018
Release: FDA Clearance of IND Application for Ciclopirox Prodrug in the Treatment of Bladder Cancer, October 2017
Kansas City Business Journal, January 25, 2017
KU Cancer Center, Children's Mercy collaboration will boost NCI effort
Kansas City Business Journal, May 10, 2016
VC firm develops first KU-invented cancer drug; FDA plans near
Kansas City Business Journal, May 3, 2016
KU, new VC fund join to speed biotech, pharma commercialization
KCBusiness Journal, March 1, 2016:
Kansas health software company acquires Phoenix business
Startland, March 1, 2016:
Behavioral health startup announces acquisition, name change
BioNovus Innovations invests in individuals and organizations that are transforming healthcare.
Disruptive innovation requires a significant financial investment and a commitment to bring novel solutions to reality. Our portfolio companies have developed new enabling technologies, pharmaceuticals and delivery models that are transformative.
Join us to chart a new path, one that addresses root causes rather than symptoms and collectively transforms the future of healthcare.
BioNovus is about partnerships.
The most successful partnerships produce a synergy that can accomplish much more than either side could alone. Partnering the right investor to the right potential breakthrough can spell the difference between success and failure for many promising therapies.
The organizations that become our partners are each unique, yet they are all trailblazing paths that have the power to transform and save countless lives.
BioNovus is proud to partner with these outstanding organizations.